Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Alfred

Showing results (401-410 of 434) with videos related to

Pageof 44
Sort By:
European Urology|March 16, 2024
Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31]J Alfred Witjes, Harman Max Bruins, Albert Carrión, et al.
Prostate Cancer and Prostatic Diseases|July 13, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancerBastiaan M Privé, Peter H J Slootbeek, Babette I Laarhuis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2023
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer GroupAshish M Kamat, Andrea B Apolo, Marek Babjuk, et al.
Cancers|January 8, 2023
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective StudyAmina Banda, Bastiaan M Privé, Youssra Allach, et al.
Journal for Immunotherapy of Cancer|November 16, 2019
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancerHarm Westdorp, Jeroen H A Creemers, Inge M van Oort, et al.
The Lancet. Oncology|December 16, 2014
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trialCora N Sternberg, Iwona Skoneczna, J Martijn Kerst, et al.
World Journal of Urology|August 16, 2018
ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancerLeonardo L Monteiro, J Alfred Witjes, Piyush K Agarwal, et al.
Cancer|November 16, 2019
Platinum exposure and cause-specific mortality among patients with testicular cancerHarmke J Groot, Flora E van Leeuwen, Sjoukje Lubberts, et al.
BMC Cancer|September 15, 2020
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
ESMO Open|March 6, 2022
Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancerN Beije, I E de Kruijff, J J de Jong, et al.
Pageof 44

Showing results (401-410 of 434) with videos related to

Sort By:
Pageof 44
European Urology|March 16, 2024
Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31]J Alfred Witjes, Harman Max Bruins, Albert Carrión, et al.
Prostate Cancer and Prostatic Diseases|July 13, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancerBastiaan M Privé, Peter H J Slootbeek, Babette I Laarhuis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2023
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer GroupAshish M Kamat, Andrea B Apolo, Marek Babjuk, et al.
Cancers|January 8, 2023
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective StudyAmina Banda, Bastiaan M Privé, Youssra Allach, et al.
Journal for Immunotherapy of Cancer|November 16, 2019
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancerHarm Westdorp, Jeroen H A Creemers, Inge M van Oort, et al.
The Lancet. Oncology|December 16, 2014
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trialCora N Sternberg, Iwona Skoneczna, J Martijn Kerst, et al.
World Journal of Urology|August 16, 2018
ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancerLeonardo L Monteiro, J Alfred Witjes, Piyush K Agarwal, et al.
Cancer|November 16, 2019
Platinum exposure and cause-specific mortality among patients with testicular cancerHarmke J Groot, Flora E van Leeuwen, Sjoukje Lubberts, et al.
BMC Cancer|September 15, 2020
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
ESMO Open|March 6, 2022
Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancerN Beije, I E de Kruijff, J J de Jong, et al.
Pageof 44